2 428

Cited 7 times in

A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status

DC FieldValueLanguage
dc.contributor.author노성훈-
dc.contributor.author노재경-
dc.contributor.author라선영-
dc.contributor.author이수현-
dc.contributor.author정재헌-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.date.accessioned2015-04-24T17:30:44Z-
dc.date.available2015-04-24T17:30:44Z-
dc.date.issued2009-
dc.identifier.issn0030-2414-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105538-
dc.description.abstractPURPOSE: We investigated the efficacy and safety of weekly paclitaxel monotherapy in previously treated patients with advanced gastric cancer (AGC) and poor performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG). PATIENTS AND METHODS: Patients with evaluable disease who failed at least one previous chemotherapy and had a PS of 2-3, received paclitaxel 70 mg/m(2) on days 1, 8 and 15 every 4 weeks. RESULTS: The median overall survival (OS) was 5.5 months (95% confidence interval, CI, 3.3-7.8) and progression-free survival was 2.1 months (95% CI, 1.2-3.0). The overall response rate was 3.8% and the disease control rate was 25.0%. Treatment-related toxicities were tolerable. OS was 7.1 (95% CI, 5.4-9.5) and 3.7 months (95% CI, 2.1-5.3) for patients with PS-ECOG 2 and 3, respectively (p < 0.001). When evaluated according to the previous treatment, OS was 5.1 (95% CI, 3.3-7.0) and 6.5 months (95% CI, 3.8-9.3) for patients receiving two and three or more lines of treatment, respectively (p = 0.815). With multivariate analysis, PS was a significant factor for OS. CONCLUSION: Survival in patients treated with weekly paclitaxel monotherapy was comparable to other second- or third-line chemotherapies for AGC, with acceptable toxicities in previously treated patients with poor PS.-
dc.description.statementOfResponsibilityopen-
dc.format.extent349~357-
dc.relation.isPartOfONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents, Phytogenic/therapeutic use*-
dc.subject.MESHFeasibilityStudies-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPaclitaxel/adverse effects-
dc.subject.MESHPaclitaxel/therapeutic use*-
dc.subject.MESHPrognosis-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/mortality-
dc.titleA phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학)-
dc.contributor.googleauthorChong Kun Im-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorHei-Cheul Jeung-
dc.contributor.googleauthorJaeheon Jeong-
dc.contributor.googleauthorSoo Hyeon Lee-
dc.contributor.googleauthorSung Hoon Noh-
dc.contributor.googleauthorJae Kyung Roh-
dc.contributor.googleauthorHyun Cheol Chung-
dc.identifier.doi10.1159/000265941-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01281-
dc.contributor.localIdA01290-
dc.contributor.localIdA03714-
dc.contributor.localIdA03773-
dc.contributor.localIdA02898-
dc.contributor.localIdA03794-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ02416-
dc.identifier.eissn1423-0232-
dc.identifier.pmid20016228-
dc.identifier.urlhttp://www.karger.com/Article/FullText/265941-
dc.subject.keywordAdvanced gastric cancer-
dc.subject.keywordPaclitaxel monotherapy-
dc.subject.keywordPoor performance status-
dc.subject.keywordWeekly paclitaxel-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameLee, Soo Hyeon-
dc.contributor.alternativeNameJung, Jae Hun-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorRoh, Jae Kyung-
dc.contributor.affiliatedAuthorJung, Jae Hun-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorLee, Soo Hyeon-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.citation.volume77-
dc.citation.number6-
dc.citation.startPage349-
dc.citation.endPage357-
dc.identifier.bibliographicCitationONCOLOGY, Vol.77(6) : 349-357, 2009-
dc.identifier.rimsid44339-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.